Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers.  Our mission is to apply this new class of biomarker to both improve assessment of individual cancer risk as well as to dramatically change how we personalize treatment.  We are dedicated to making our discoveries fully accessible to all those who can benefit from them.